Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 4/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13069461 | 1.00 | CLK4 (0.40) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3373888 | 1.00 | CLK4 (0.40) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14337693 | 0.84 | BRD4 (0.32) | CLK4LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3373570 | 0.84 | BRD4 (0.32) | CLK4LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3372767 | 0.84 | BRD4 (0.32) | CLK4LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13069006 | 0.83 | VNN1 (0.39) | LMNAALDH1A1TSHRHIF1ATP53 | |
| SCHEMBL3372593 | 0.83 | VNN1 (0.39) | LMNAALDH1A1TSHRHIF1ATP53 | |
| SCHEMBL3372598 | 0.83 | VNN1 (0.39) | LMNAALDH1A1TSHRHIF1ATP53 | |
| SCHEMBL5573283 | 0.82 | PKM (0.38) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL5570169 | 0.82 | PKM (0.38) | CLK4CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | claimed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | claimed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | claimed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | claimed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | claimed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | CDK4, CDK1, CDK14 | CLK4 287/4885CYP1A2 1474/4885CYP3A4 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.